Matched weight loss through liraglutide or lifestyle similarly improved liver fat in MASLD, but GLP-1 therapy additionally reduced de novo lipogenesis, and withdrawal caused adverse changes in circulating proteins and gene expression that may drive weight regain.
Equal liver benefit, extra metabolic advantagesMatched weight loss through liraglutide or lifestyle equally improved liver fat, but GLP-1 therapy also reduced de novo lipogenesis — and withdrawal triggered adverse inflammatory and gene expression changes
What the researchers found
In 29 MASLD patients without diabetes, after 12 weeks of matched weight loss:
Similar between groups:
- Body composition changes, ALT reduction, liver steatosis reduction, and disease activity improvement
- Subcutaneous adipose transcriptome, circulating proteome, and stool microbiome
GLP-1RA advantages:
- Improved glucose handling and fasting lipids
- Significantly decreased de novo lipogenesis (DNL)
After treatment withdrawal (12 weeks):
- GLP-1RA (but not lifestyle) group showed elevated MMP-10, IL10RB, FGF-23, and Flt3L in circulation
- Dysregulated adipose tissue gene expression
- Changes suggestive of metabolic predisposition to weight regain
Why it matters
This study addresses two critical questions: Does GLP-1 therapy provide liver benefits beyond weight loss? And what happens metabolically when you stop? The answers — yes to extra benefits, and concerning rebound effects — have major implications for clinical practice. They support using GLP-1 drugs in MASLD while raising important questions about the consequences of treatment discontinuation.
How the study worked
Prospective, randomized experimental medicine study (EudraCT 2016-002045-36). 29 MASLD participants without T2D were randomized to lifestyle (~500 kcal deficit) or liraglutide for 12 weeks. Comprehensive phenotyping included de novo lipogenesis, liver MRI, body composition, adipose tissue RNA sequencing, circulating proteome, and stool microbiome. All investigations repeated after treatment and 12 weeks post-withdrawal.
What this study cannot tell us
Small sample size (29 participants) limits statistical power. The 12-week treatment duration is relatively short. Only liraglutide was tested; other GLP-1 RAs may differ. The lifestyle group's adherence to calorie restriction after the study period wasn't tracked. Some withdrawal changes (proteome, microbiome) are exploratory and hypothesis-generating rather than confirmatory.
How to read the evidence
This is a small, prospective, randomized experimental medicine study with deep molecular phenotyping. While the study design is rigorous, the sample size is small and some findings are exploratory.
When this study was published
Published in 2025, this is very current research addressing the critical clinical questions of GLP-1 drug mechanisms in fatty liver disease and the consequences of treatment cessation.
The bigger picture
Weight regain after stopping GLP-1 drugs is a major clinical concern. This study goes beyond just documenting weight rebound to show specific molecular changes — elevated inflammatory markers and disrupted fat tissue gene expression — that may actively drive weight regain. Understanding these withdrawal effects could lead to better strategies for tapering or transitioning patients off GLP-1 therapy, and supports the concept that these drugs may need long-term use for sustained benefit.
Questions still open
- Can the metabolic disruptions seen after GLP-1 withdrawal be prevented by gradual dose tapering?
- Do the elevated inflammatory markers after withdrawal contribute to MASLD recurrence?
- Would combining GLP-1 therapy with lifestyle changes prevent the rebound effects seen after drug withdrawal?
Common questions
Do GLP-1 drugs help fatty liver disease beyond just weight loss?
What happens when you stop taking a GLP-1 drug?
Read the original research
Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD.
JHEP reports : innovation in hepatology, 7(5), 101363
Citation
Moolla, Ahmad; Poolman, Toryn; Othonos, Nantia; Dong, Jiawen; Smith, Kieran; Cornfield, Thomas; White, Sarah; Ray, David W; Mouchti, Sofia; Mózes, Ferenc E; Thomaides-Brears, Helena; Neubauer, Stefan; Cobbold, Jeremy F; Hodson, Leanne; Tomlinson, Jeremy W. (2025). Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD.. JHEP reports : innovation in hepatology, 7(5), 101363. https://doi.org/10.1016/j.jhepr.2025.101363